Drug Trial Radar · NCT04121221
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,016
Actual
Start
Sep 19, 2019
Primary completion
Jun 13, 2023
Study completion Jun 13, 2023
Sponsor
- Lead sponsor
- Mapi Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
GA DepotDrug
Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
PlaceboOther
IM injection once every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: 52 weeks
Locations
112 sites in 10 countries. Site status is shown where the registry gives one.
Mapi Pharma Research site 08
Birmingham, Alabama
Mapi Pharma Research site 11
Cullman, Alabama
Mapi Pharma Research site 15
Pasadena, California
Mapi Pharma Research site 14
Denver, Colorado
Mapi Pharma Research site 12
Washington D.C., District of Columbia
Mapi Pharma Research site 17
Homestead, Florida
Mapi Pharma Research site 09
Miami, Florida
Mapi Pharma Research site 01
Northbrook, Illinois
Mapi Pharma Research site 02
Detroit, Michigan
Mapi Pharma Research site 13
Westerville, Ohio
Mapi Pharma Research site 04
Round Rock, Texas
Mapi Pharma Research site 02
Homyel, Belarus
Mapi Pharma Research site 04
Minsk, Belarus
Mapi Pharma Research site 05
Minsk, Belarus
Mapi Pharma Research site 06
Minsk, Belarus
Mapi Pharma Research site 01
Vitebsk, Belarus
Mapi Pharma Research site 07
Vitebsk, Belarus
Mapi Pharma Research site 04
Banja Luka, Bosnia and Herzegovina
Mapi Pharma Research site 06
Bihać, Bosnia and Herzegovina
Mapi Pharma Research site 01
Sarajevo, Bosnia and Herzegovina
Mapi Pharma Research site 03
Tuzla, Bosnia and Herzegovina
Mapi Pharma Research site 14
Haskovo, Bulgaria
Mapi Pharma Research site 10
Pazardzhik, Bulgaria
Mapi Pharma Research site 01
Pleven, Bulgaria
Mapi Pharma Research site 02
Pleven, Bulgaria
Mapi Pharma Research site 03
Pleven, Bulgaria
Mapi Pharma Research site 07
Pleven, Bulgaria
Mapi Pharma Research site 12
Plovdiv, Bulgaria
Mapi Pharma Research site 18
Rousse, Bulgaria
Mapi Pharma Research site 04
Sofia, Bulgaria
Mapi Pharma Research site 05
Sofia, Bulgaria
Mapi Pharma Research site 06
Sofia, Bulgaria
Mapi Pharma Research site 08
Sofia, Bulgaria
Mapi Pharma Research site 11
Sofia, Bulgaria
Mapi Pharma Research site 13
Sofia, Bulgaria
Mapi Pharma Research site 15
Sofia, Bulgaria
Mapi Pharma Research site 16
Sofia, Bulgaria
Mapi Pharma Research site 19
Sofia, Bulgaria
Mapi Pharma Research site 09
Veliko Tarnovo, Bulgaria
Mapi Pharma Research site 17
Vratsa, Bulgaria
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.